ÂÜÀòÂÒÂ×

Dr. Sanders has served on the board of directors at Legend Biotech since May 2020. Dr. Sanders has also been a member of the board of directors at Molecular Templates, Inc. since December 2019 and at AbGenomics since March 2020.

Dr. Sanders previously served as the Strategic Advisor to the Office of the Celgene Chief Medical Officer from March 2018 to November 2019. Her responsibilities included ensuring effective integration of Juno’s Development Organization into the Celgene Organization, specifically the unique chimeric antigen receptor T-cell (CAR-T) aspects, advising the label-enabling CAR-T legacy Juno program (JCAR017), and advising the Chief Medical Officer and his leadership team on evolving the clinical development organization.

Prior to her role as Strategic Advisor, Dr. Sanders was a Member of the Juno Therapeutics Executive Committee as Executive Vice President of Development Operations, with responsibilities for strategic operations, quantitative sciences, biosample and clinical operations from January 2017 to March 2018.

Dr. Sanders was a Member of the Genentech/Roche Late Stage Portfolio Committee from 2009 to 2017, and Global Head of the Genentech/Roche Late Stage Clinical Operations from 2012 to 2017, with responsibility for leading employees in planning and conducting global development and local clinical trials in over 70 countries.

Dr. Sanders has directly contributed and/or provided oversight in developing multiple pharmaceutical products, including a CAR-T cell therapy for Non-Hodgkin lymphoma.

Dr. Sanders holds a Bachelor of Science and a Master of Science in statistics, graduating Magna Cum Laude from the University of the Philippines, Philippines. She also received a Master of Arts and a Doctor in Philosophy in statistics from the Wharton Doctoral Program at the University of Pennsylvania, USA.